Streetbeat News

BIAF

bioAffinity Technologies, Inc.

https://www.bioaffinitytech.com

Industry

Medical - Diagnostics & Research

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Open

1.33

Mkt cap

19M

Volume

61K

High

1.33

P/E Ratio

-1.53

52-wk high

3.62

Low

1.22

Div yield

N/A

52-wk low

1.21

bioAffinity Technologies' CyPath Lung test could save significant healthcare costs by reducing unnecessary follow-ups and complications in lung cancer detection, as per a peer-reviewed study. The test could have saved $379 million in 2022 for Medicare patients.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:10 pm

bioAffinity Technologies has appointed J. Michael Edwards as the interim CFO following the resignation of Michael Dougherty.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 6:50 am

bioAffinity Technologies (NASDAQ:BIAF) reported Q2 EPS of $(0.19), an improvement from $(0.20) YoY, and sales of $2.40M, a significant increase from $19.74K YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 1:27 pm

U.S. stocks fell significantly with the Nasdaq Composite dropping 3% amid disappointing economic data. Nonfarm payrolls increased by 114,000 in July, below expectations, and the unemployment rate rose to 4.3%. Several stocks experienced notable price movements, including VSee Health, Exicure, Tandem Diabetes Care, bioAffinity Technologies, Gamer Pakistan, and Fresh Vine Wine.

Portfolio Pulse from Avi Kapoor

August 02, 2024 | 4:02 pm

bioAffinity Technologies shares are trading lower following the pricing of a registered direct offering and concurrent private placement.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 3:33 pm

U.S. stocks traded lower with the Dow Jones index dipping over 400 points. Apple reported better-than-expected earnings. VSee Health, Exicure, and OS Therapies saw significant stock price increases, while bioAffinity Technologies, Gamer Pakistan, and Fresh Vine Wine experienced notable declines.

Portfolio Pulse from Avi Kapoor

August 02, 2024 | 1:52 pm

bioAffinity Technologies has entered into warrant exercise agreements for the immediate exercise of 1,041,667 shares, generating $1.3 million in gross proceeds. The company has issued new warrants for 1,302,083 shares at $1.50 per share and reduced the exercise price of existing warrants to $1.25. Additionally, a securities purchase agreement for 360,000 shares and private warrants for 450,000 shares at $1.25 per unit is expected to close on August 5, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 1:26 pm

Maxim Group has initiated coverage on bioAffinity Technologies (NASDAQ:BIAF) with a Buy rating and a price target of $6, as announced by analyst Anthony Vendetti.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 1:54 pm

bioAffinity Technologies, Inc. (NASDAQ:BIAF) reported a 139% growth in the number of pulmonology practices and physicians offering its CyPath® Lung test since January 1, 2024. The company is ahead of forecasts in onboarding pathology practices.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 12:11 pm

bioAffinity Technologies (NASDAQ:BIAF) reported Q1 EPS of $(0.21), a 16.67% decrease from $(0.18) YoY, and sales of $2.41M, a significant increase from $921.00 YoY.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 1:28 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.